A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.
Goldstein
J A
JA
Blaisdell
J A
JA
Limdi
N A
NA
D001741:Black or African American / Q000235:genetics*; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001281:Atrial Fibrillation / Q000188:drug therapy; D015897:Comorbidity; D065729:Cytochrome P-450 CYP2C9; D004252:DNA Mutational Analysis; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017422:Sequence Analysis, DNA; D014859:Warfarin / Q000009:adverse effects* / Q000493:pharmacokinetics
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases